Lifeline Biotech

Lifeline Biotechnologies is a medical technology company primarily focused on the development and commercialization of non-invasive diagnostic tools for the early detection of breast cancer. The company's core technology, the First Warning System, uses sophisticated thermal sensors and neural network algorithms to monitor circadian temperature changes in breast tissue. These changes can indicate the presence of early-stage malignancies, potentially before they are detectable by traditional imaging methods like mammography. This technology is designed to serve as an adjunct to traditional screening, particularly for women with dense breast tissue where mammograms may be less effective. Lifeline Biotechnologies holds a portfolio of intellectual property related to these diagnostic methods and has historically partnered with other firms for clinical validation and international distribution. The company is publicly traded and continues to seek pathways for broader regulatory approval and market adoption of its diagnostic platform.